Results 101 to 110 of about 77,126 (266)

Early diuretic response and outcome prediction in ambulatory worsening heart failure: Natriuresis versus diuresis

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Early diuresis and natriuresis are commonly used to assess the efficacy of decongestive therapy following an acute heart failure episode. There is limited knowledge regarding which parameter better predicts adverse clinical outcomes, especially in the outpatient setting.
M. Cobo Marcos   +15 more
wiley   +1 more source

Angiopoietin-2 predicts morbidity in adults with Fontan physiology. [PDF]

open access: yes, 2019
Morbidity in patients with single-ventricle Fontan circulation is common and includes arrhythmias, edema, and pulmonary arteriovenous malformations (PAVM) among others. We sought to identify biomarkers that may predict such complications.
Aboulhosn, Jamil A   +8 more
core  

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai   +4 more
wiley   +1 more source

Prescription of guideline‐directed medical therapy in heart failure: impact on mortality and readmission

open access: yesESC Heart Failure, EarlyView.
Routine data analysis showing a better outcome regarding mortality and readmission in HF patients when being prescribed the current four‐drug treatment (vs. the outdated two‐drug therapy) 91–365 days after index hospital stay. Abstract Aims The 2021 European heart failure (HF) guidelines recommend the combination of four drugs as a standard therapy ...
Martin Möckel   +9 more
wiley   +1 more source

Cardiogenic shock: do not forget the possibility of Kawasaki disease

open access: yesThe Turkish Journal of Pediatrics, 2012
We report the case of a six-year-old boy who presented with cardiogenic shock due to Kawasaki disease (KD). He was misdiagnosed at first as septic shock.
Wei Wang   +4 more
doaj  

Immune Checkpoint Inhibitors and Cardiovascular Adverse Events

open access: yesESC Heart Failure, EarlyView.
Abstract In the last years, we assisted to a tremendous increase in therapeutic options for the management of cancers, with immunotherapy at the forefront of this innovation. Immune checkpoint inhibitors (ICIs) have been developed to enhance the activity of the immune system against cancer cells (1) and the number of approvals for ICIs has rapidly ...
Maria Luisa De Perna   +4 more
wiley   +1 more source

Clinical outcomes following shock team implementation for cardiogenic shock: a systematic review

open access: yesThe Egyptian Heart Journal
Background Cardiogenic shock is a critical cardiac condition characterized by low cardiac output leading to end-organ hypoperfusion and associated with high in-hospital mortality rates.
Mohamed Abdelnabi   +6 more
doaj   +1 more source

Houston SHOCK: A Practical Scoring System Incorporating Cardiogenic Shock Dynamic Changes [PDF]

open access: yes, 2022
Cardiogenic shock has an unacceptably high mortality rate and additional tools are needed to improve outcomes. The Society of Cardiovascular Angiography and Interventions (SCAI) shock severity classification has provided a unified definition of shock ...
Gregoric, Igor D   +3 more
core   +1 more source

Multicentre comparison of various microaxial pump devices as a bridge to durable assist device implantation

open access: yesESC Heart Failure, EarlyView.
In the context of patients with severe heart failure, it is crucial to ensure adequate preconditioning before considering the implantation of dLVAD. Although several types of mechanical circulatory assist devices are available and all offer a significant advantage, the present study suggests that the higher the flow rate provided by the Impella®, the ...
Marta L. Medina   +32 more
wiley   +1 more source

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

open access: yesESC Heart Failure, EarlyView.
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in clinical practice, it remains challenging to identify the appropriate timing to start SGLT2 ...
Ruggero Mazzotta   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy